|
|
|
|
LEADER |
03344nam a22004815i 4500 |
001 |
978-3-7091-1818-4 |
003 |
DE-He213 |
005 |
20150519174605.0 |
007 |
cr nn 008mamaa |
008 |
141113s2014 au | s |||| 0|eng d |
020 |
|
|
|a 9783709118184
|9 978-3-7091-1818-4
|
024 |
7 |
|
|a 10.1007/978-3-7091-1818-4
|2 doi
|
040 |
|
|
|d GrThAP
|
050 |
|
4 |
|a RM281
|
050 |
|
4 |
|a QR189-189.5
|
072 |
|
7 |
|a MJCM
|2 bicssc
|
072 |
|
7 |
|a MED044000
|2 bisacsh
|
082 |
0 |
4 |
|a 615.372
|2 23
|
245 |
1 |
0 |
|a Novel Technologies for Vaccine Development
|h [electronic resource] /
|c edited by Igor S Lukashevich, Haval Shirwan.
|
264 |
|
1 |
|a Vienna :
|b Springer Vienna :
|b Imprint: Springer,
|c 2014.
|
300 |
|
|
|a XIV, 386 p. 35 illus., 33 illus. in color.
|b online resource.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
347 |
|
|
|a text file
|b PDF
|2 rda
|
505 |
0 |
|
|a Reverse Genetics Approaches for Rational Design of Inactivated and Live-Attenuated Influenza Vaccines -- Viral-Vectored Vaccines to Control Pathogenic Filoviruses -- Alphavirus Replicon Vectors for Prophylactic Applications and Cancer Intervention -- Current Status and Future of Polio Vaccines and Vaccination -- Current Status of Hantavirus Vaccines Development -- Experimental DNA-Launched Live Attenuated Vaccines against Infections Caused by Flavi- and Alphaviruses -- Sugar-Based Immune Adjuvants for Use in Recombinant, Viral, Vector, DNA and Other Styles of Vaccines -- Adenovirus-based Vectors for the Development of Prophylactic and Therapeutic Vaccines -- Radiovirotherapy for the Treatment of Cancer -- TRICOM Poxviral-Based Vaccines for the Treatment of Cancer -- The Use of Oncolytic Herpesvirus for the Treatment of Cancer -- SA-4-1BBL; A Novel form of the 4-1BB Costimulatory Ligand as an Adjuvant Platform for the Development of Subunit Cancer Vaccines.
|
520 |
|
|
|a This book presents a detailed overview of the development of new viral vector-based vaccines before discussing two major applications: preventive vaccines for infectious diseases and therapeutic cancer vaccines. Viral vector-based vaccines hold a great potential for development into successful pharmaceutical products and several examples at the advanced pre-clinical or clinical stage are presented. Nevertheless, the most efforts were focused on novel and very innovative technologies for new generation of vector-based vaccines. Furthermore, specific topics such as delivery and adjuvant and protection strategies for cell-mediated-based vaccines are presented. Given its scope, the book is a “must read” for all those involved in vaccine development, both in academia and industrial vaccine development.
|
650 |
|
0 |
|a Medicine.
|
650 |
|
0 |
|a Immunology.
|
650 |
|
0 |
|a Vaccines.
|
650 |
|
0 |
|a Pharmaceutical technology.
|
650 |
1 |
4 |
|a Biomedicine.
|
650 |
2 |
4 |
|a Vaccine.
|
650 |
2 |
4 |
|a Pharmaceutical Sciences/Technology.
|
650 |
2 |
4 |
|a Immunology.
|
700 |
1 |
|
|a Lukashevich, Igor S.
|e editor.
|
700 |
1 |
|
|a Shirwan, Haval.
|e editor.
|
710 |
2 |
|
|a SpringerLink (Online service)
|
773 |
0 |
|
|t Springer eBooks
|
776 |
0 |
8 |
|i Printed edition:
|z 9783709118177
|
856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-3-7091-1818-4
|z Full Text via HEAL-Link
|
912 |
|
|
|a ZDB-2-SBL
|
950 |
|
|
|a Biomedical and Life Sciences (Springer-11642)
|